Browsing ODA Open Digital Archive by Subject "Internal dosimetries"
Now showing items 1-1 of 1
-
Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-Radionuclide conjugate 177Lu-Lilotomab satetraxetan
(Journal of Nuclear Medicine;April 1, 2018; Vol. 59, no. 4, Journal article; Peer reviewed, 2018-08-28)177Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate (ARC) currently in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non Hodgkin lymphoma (NHL). The ...